Orthopedic surgery ·
FDA approves prodisc C Nova for two-level use; robotic lumbar fusion tied to less opioid use; 3D-printed cervical implant cleared
Listen to this post
read by AI voices · all episodesTHE SHORT READ
The Food and Drug Administration (FDA) approved Centinel Spine's prodisc C Nova cervical disc for two-level use, the company said Oct. 14. At the North American Spine Society meeting, Hospital for Special Surgery reported less opioid use after robotic lumbar fusion and Globus Medical previewed a patient-specific implant platform, and Providence Medical Technology announced clearance of a 3D-printed cervical implant.
THE DETAILS
- FDA Oct 14, 2026Centinel Spine said Oct. 14 that the Food and Drug Administration (FDA) approved its prodisc C Nova for two-level use, so the device is now approved for one- and two-level use. The company's prodisc C Vivo and prodisc C SK received two-level approval in October 2025. Prodisc C Nova is available on a limited-release basis in the U.S. and has been in clinical use outside the U.S. since 2009, the company said.
- Research Oct 15, 2026Hospital for Special Surgery (HSS) researchers used a prospectively maintained registry to compare 601 robotic-assisted and 203 navigation-guided one- or two-level lumbar fusions done from 2017 to 2025. Robotic surgery was associated with a 16% reduction in total in-hospital opioid consumption, 21% less opioid use in the first 24 hours and a 57% lower likelihood of needing patient-controlled analgesia, with no significant differences in complications or length of stay, according to HSS. The results were presented at the North American Spine Society meeting.Source: Ortho Spine News (HSS release)
- FDA Oct 13, 2026Providence Medical Technology said Oct. 13 that it received 510(k) clearance from the Food and Drug Administration for the CORUS PCSS 3D-T, indicated to immobilize and stabilize spinal segments as an adjunct to posterior cervical fusion. The new version adds a porous titanium lattice engineered to mimic cancellous bone, with 1.5 times the surface area of the original machined implant, according to the company. The company said a randomized trial of the earlier CORUS device showed higher fusion rates at 12 and 24 months when it was combined with multilevel anterior fusion than with anterior fusion alone.
- Technology Oct 14, 2026Globus Medical said Oct. 14 that it would give an early look at SCRIPT, its new patient-specific spinal implant platform, at the North American Spine Society meeting, held Oct. 14 to 17 in San Antonio. In SCRIPT Studio, surgeons maintain control of preoperative planning and implant design, and plans can be imported into the company's ExcelsiusGPS or ExcelsiusHub systems. The company called SCRIPT FDA-cleared technology and said it is moving toward commercialization.
The weekly innovation roundup for orthopedic surgery, published every Sunday for the week before; every item links to its sources. Latest orthopedic surgery news · All specialties